Verve Therapeutics, Inc.

Verve Therapeutics, Inc. insiders are currently net buyers of VERV stock, showing neutral sentiment over the past 90 days. Executives have purchased $85.9M while selling $48.8M, resulting in a positive net flow of $37.1M. This buying activity represents 64% of total transaction volume.

Verve Therapeutics, Inc. has 35 active insiders who have filed SEC Form 4 transactions in the past 90 days. Krishna Yeshwant (Executive) leads with 29 transactions totaling $25.4M. Partners Master Fund, L.p. Casdin (Executive) follows with 3 transactions worth $20.9M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Verve Therapeutics, Inc.'s current score of 64/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $85.9M in purchases versus $48.8M in sales.

The most recent insider transaction occurred on Jul 25, 2025, when D. Ashe Andrew (Executive) disposed of 348,828 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, VERV insider trading sentiment is currently neutral with an Alignment Score of 64/100. The net insider flow of $37.1M reflects accumulation, with 64% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Verve Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At VERV, we track all Form 4 filings—currently showing 208 transactions from 35 insiders over 90 days.

A 10b5-1 plan allows Verve Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At VERV, approximately 6% of recent transactions are 10b5-1 trades. The remaining 94% are discretionary trades, which may carry more informational value.

You can monitor Verve Therapeutics, Inc. (VERV) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 35 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Verve Therapeutics, Inc.'s current score of 64/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $85.9M in purchases versus $48.8M in sales over 90 days, resulting in a net flow of $37.1M.

SEC Form 4 filings are mandatory reports that Verve Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At VERV, the most common type is "A" with 21 occurrences. The most recent Form 4 was filed on Jul 25, 2025 by D. Ashe Andrew.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Verve Therapeutics, Inc., approximately 6% of recent transactions are executed under 10b5-1 plans, while 94% appear to be discretionary trades. The low percentage means most insider activity at VERV represents discretionary decisions with more informational value.